Page Mission:
The purpose of this page is to provide a forum for individuals to learn more about Inozyme’s products and technology and get connected to our clinical trials.
Page Community Standards and Rules:
Facebook community standards will govern this page as well as our page rules listed below. Individuals found violating any of the rules may find their post removed and may be banned from future engagement on our page.
• Respect everyone’s privacy
• No hateful or discriminatory comments regarding race, ethnicity, religion, gender, disability, sexual orientation or political beliefs
• No links or comments containing sexually explicit content material
• No violations of copyright or intellectual property rights
• No spam, link baiting or files containing viruses that could damage the operation of other people’s computers or mobile devices
• No attacks meant to harass, threaten or abuse an individual
• No commercial solicitations or the promotion of a competitor
The purpose of this page is to provide a forum for individuals to learn more about Inozyme’s products and technology and get connected to our clinical trials.
Page Community Standards and Rules:
Facebook community standards will govern this page as well as our page rules listed below. Individuals found violating any of the rules may find their post removed and may be banned from future engagement on our page.
• Respect everyone’s privacy
• No hateful or discriminatory comments regarding race, ethnicity, religion, gender, disability, sexual orientation or political beliefs
• No links or comments containing sexually explicit content material
• No violations of copyright or intellectual property rights
• No spam, link baiting or files containing viruses that could damage the operation of other people’s computers or mobile devices
• No attacks meant to harass, threaten or abuse an individual
• No commercial solicitations or the promotion of a competitor
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $116M
Founded date: 2016
Investors 7
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | K2 HealthV... | k2healthve... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | NFLS - Piv... | pivotalbio... |
| - | Longitude ... | longitudec... |
| - | K2 HealthV... | k2hv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.04.2019 | Series A | $67M | - |
| 15.11.2017 | Series A | $49M | New Enterp... |
Mentions in press and media 22
| Date | Title | Description |
| 01.04.2025 | The Future of Genomic Insights: A New Era in Precision Medicine | In the realm of healthcare, data is the new gold. As we venture deeper into the age of precision medicine, the need for comprehensive genomic insights has never been more critical. Two companies, Genomize and Genomenon, are at the forefront... |
| 01.04.2025 | Genomenon Unlocks Real-World Evidence for Precision Therapeutics Developers | Genomenon logo Novel AI solution extracts real-world insights from clinical literature to inform rare disease and cancer research ANN ARBOR, Mich., April 1, 2025 /PRNewswire-PRWeb/ -- Genomenon, a leading provider of genomic intelligence, t... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 12.03.2024 | Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights | - |
| 31.10.2022 | New Study Presents Novel Solution to Increasing Diagnostic Yield and Accelerating Diagnosis of Rare Disease | "Our partnership with Inozyme puts critical information about ENPP1 Deficiency at the fingertips of doctors...and will play a key role in addressing missed diagnoses, which has long been a challenge for this disease community.” – Dr. M... |
| 26.07.2022 | Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures | BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has e... |
| 11.11.2021 | Genomenon and Inozyme Pharma Announce Partnership to Advance Genetic Diagnosis for Rare Disease Patients | “Genomenon’s AI-driven data has the potential to greatly increase our collective understanding of ENPP1 Deficiency.” – Axel Bolte, Inozyme Pharma ANN ARBOR, Mich. (PRWEB) November 11, 2021 Genomenon, Inc.®, an AI-driven genomics company, an... |
| 01.12.2020 | Slone Partners Places Kevin B. Johnson as Senior Vice President of Regulatory Affairs at Inozyme Pharma | “Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless. SOUTH RIDING, Va. (PRWEB) December 01, 2020 Sl... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IP... |
Show more